Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4CNS 3Sarcoma 2Head & Neck 2Genitourinary 2Endocrine 2Other solid neoplasm 1Other hematologic neoplasm 1NET 1Lymphoid 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Thyroid Cancer, Papillary 1Sarcoma 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

lutetium Lu 177 dotatate 13Magnetic Resonance Spectroscopy 6Specimen Handling 5pembrolizumab 4cabozantinib 4Nivolumab 4Octreotide 3Lutetium-177 3Ipilimumab 3Everolimus 3lenvatinib 2avelumab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Temozolomide 2Phantoms, Imaging 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2toripalimab 1tislelizumab 1telotristat ethyl 1surufatinib 1peposertib 1pazopanib 1pasireotide 1entrectinib 1copper dotatate CU-64 1atezolizumab 1abemaciclib 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × entrectinib × NET × Clear all
NCT02568267 2026-05-27

STARTRK-2

Hoffmann-La Roche

Phase 2 Active not recruiting
534 enrolled 1 FDA
BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡